ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Development, characterization, and evaluation of the therapeutic efficacy of PEGylated-nanoliposomal artesunate in mice bearing non-small cell lung carcinoma.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study focused on the development of a slow-release formulation for artesunate by PEGylated-liposome nanoparticles to improve its pharmacokinetics and antitumor properties on non-small-cell lung cancer (NSCLC) cells. The lipid-film hydration method was used to entrap artesunate in the liposomal nanoformulation coated with DSPE-mPEG(2000). The physical properties of PEGylated liposomal artesunate were characterized by the dynamic light scattering technique. Its drug release, encapsulation efficiency, and pharmacokinetics were evaluated by the HPLC analysis. It effects on the survival and the metastatic activity of NSCLC cells, the A549 cell line, were evaluated. Tumor growth inhibition and survival rate were investigated in BALB/c mice bearing NSCLC. Particle size of the PEGylated liposomal artesunate was in the nano-range (135.8 ± 8.3 nm) with a high percentage of encapsulation efficiency (93.08 ± 0.83%). It showed a sustained-release profile providing high bioavailability (T
Indexed as
Identifiers
41984187What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.